MRCP UK EXAMINATIONS

Detailed explanation-1: -The standard treatment for chronic phase CML is a tyrosine kinase inhibitor (TKI) like imatinib (Gleevec), nilotinib (Tasigna), dasatinib (Sprycel), or bosutinib (Bosulif). If the first drug stops working or it never really worked well at all, the dose may be increased or another TKI might be tried.

Detailed explanation-2: -Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid leukemia (CML). Imatinib directly inhibits the constitutive tyrosine kinase activity.

Detailed explanation-3: -Imatinib (Gleevec) was the first drug to specifically target the BCR-ABL tyrosine kinase protein. Almost all CML patients respond to treatment with imatinib, and most of these responses seem to last for many years. Imatinib is taken by mouth as a pill with food, usually once a day. Generic imatinib is also available.

Detailed explanation-4: -Imatinib. A medicine called imatinib is now the main treatment for CML. It’s usually given soon after a diagnosis is made to slow the progression of the cancer and stop it reaching an advanced phase. Imatinib works by reducing the production of abnormal white blood cells.